Category: General

Clin Adv Periodontics. 2026 Feb 28. doi: 10.1002/cap.70046. Online ahead of print.

ABSTRACT

BACKGROUND: Autogenous particulate dentin has emerged as one of the promising biocompatible alternatives to traditional bone graft materials in alveolar ridge augmentation. Although its clinical success is documented, comprehensive studies combining histological and radiographic evaluations remain limited. This case report addresses this gap by detailing a novel approach using autogenous particulate dentin combined with cancellous allograft and a long-lasting absorbable barrier membrane (lasso-guided bone regeneration technique) for horizontal ridge augmentation.

METHODS AND RESULTS: A 49-year-old female presented with insufficient alveolar ridge width (Seibert Class I) at edentulous sites #12 and #14, necessitating bone augmentation before implant placement. The procedure involved a layered approach: Cancellous allograft (internal layer, faster remodeling) followed by autogenous particulate dentin (outer layer, slower remodeling). A bovine pericardium membrane was used to isolate the graft site and promote healing. Six months post-surgery, cone-beam computed tomography scans demonstrated significant alveolar ridge width gains of 4.64 mm at #12 and 4.21 mm at #14. Implants were successfully placed, and a bone core harvested at the 4-month mark confirmed the slow remodeling rate of the dentin particles compared to the allograft. One year post-restoration, the implants remain functional.

CONCLUSION: This case report highlights the efficacy of the layered approach using autogenous particulate dentin, particularly for space maintenance. The slower remodeling rate of dentin suggests its suitability as an outer layer, enhancing long-term stability. This innovative technique and material selection may represent a significant advancement in alveolar ridge augmentation procedures. Further studies are warranted to confirm these findings and determine optimal applications in the long term.

KEY POINTS: The case demonstrates that a biologically driven layered grafting approach-placing cancellous allograft internally for faster remodeling and autogenous particulate dentin externally for slower turnover and superior space maintenance-is an option to perform horizontal ridge augmentation by mimicking natural bone architecture. Histologic findings highlight that dentin particles remodel very slowly yet remain well integrated within the grafted site without complications, contributing to stability while allowing substantial formation of vital bone. This confirms that autogenous dentin serves as a reliable, long-lasting scaffold that supports new bone formation. However, long-term evaluation may still be necessary. The use of a long-lasting absorbable pericardium membrane stabilized with the lasso GBR technique ensures membrane security, space preservation, and tension-free primary closure-factors that collectively promote predictable healing and successful guided bone regeneration consistent with biology.

PLAIN LANGUAGE SUMMARY: This case report presents a new approach for rebuilding bone in the jaw to allow for dental implant placement. A 49-year-old woman had insufficient bone width in the upper jaw, which made implant treatment impossible without bone augmentation. To solve this, the treatment combined two materials: donated human bone on the inside, which remodels quickly, and the patient’s own tooth material, ground into small particles, on the outside, which remodels more slowly and helps maintain space. A protective membrane was used to stabilize the graft and promote healing. After 6 months, 3D scans showed a significant increase in bone width, allowing implants to be placed successfully. A small bone sample confirmed the slow remodeling of the tooth particles compared with the donated bone. One year after the final restoration, the implants remained functional and stable. This technique suggests that using a patient’s own tooth material, combined with other grafting materials, may provide a safe and effective alternative for jawbone reconstruction. It may also reduce the need for animal-derived products while improving long-term stability for implant treatments.

PMID:41761954 | DOI:10.1002/cap.70046

J Clin Med. 2026 Feb 8;15(4):1336. doi: 10.3390/jcm15041336.

ABSTRACT

Background/Objectives: Entelon150^® (Vitis vinifera seed extract), losartan, and rosuvastatin have been shown to be effective in reducing calcification and inflammation of bovine pericardium implants. However, no study has compared the effects of the drugs on bioprosthetic heart valve (BHV). This study aimed to compare the anti-calcification and anti-inflammatory effects of each drug in a rat model. Methods: Twenty-eight female Sprague-Dawley rats (two weeks old) were implanted with BHV leaflets in the dorsal subcutis. They were divided into control, losartan (10.3 mg/kg/day), rosuvastatin (2 mg/kg/day), and Entelon150^® (30.8 mg/kg/day) groups. Eight weeks later, the calcium level and inflammatory cell infiltration in the BHV leaflets as well as the expression levels of IL-6, osteopontin, and BMP-2 in the surrounding tissues were measured. Results: Losartan-, Entelon150^®-, and rosuvastatin-treated groups showed a decrease in the calcium content as compared to the control group in the order. A reduction in the inflammatory cell infiltration was observed in the treatment groups (losartan > Entelon150^® > rosuvastatin) as compared to that in the control group. The treatment groups showed a decrease in IL-6, OPN, and BMP-2 expression levels as compared to the control group in the following order: Entelon150^® > losartan > rosuvastatin. Conclusions: The calcification of the BHV leaflets and inflammation of the surrounding tissues in treatment groups were lower than those in the control group and were comparable to each other. Entelon150^® showed comparable anti-inflammatory and anti-calcification effects and may represent a potential therapeutic candidate for prolonging BHV durability, although further validation is required.

PMID:41753024 | PMC:PMC12941210 | DOI:10.3390/jcm15041336

Cureus. 2026 Jan 11;18(1):e101321. doi: 10.7759/cureus.101321. eCollection 2026 Jan.

ABSTRACT

Carotid artery stenting (CAS) is a well-established alternative to carotid endarterectomy (CEA) for the treatment of carotid artery stenosis, particularly in patients at high surgical risk. However, in-stent restenosis (ISR) remains a notable long-term complication, occurring in up to 20% of patients within five years. The optimal management strategy for ISR remains unclear, as endovascular reintervention carries a significant risk of recurrence, and evidence supporting surgical explantation is limited. We present two patients who developed severe carotid ISR and were successfully treated with CEA and complete stent explantation followed by bovine pericardial patch angioplasty. The first patient, an 84-year-old woman with bilateral carotid disease and a history of left carotid stenting, developed 90% restenosis at surveillance and underwent staged bilateral carotid revascularization with durable patency at three-year follow-up. The second patient, a 70-year-old man, presented with acute visual loss and imaging demonstrating near-occlusive thrombosis within a previously placed carotid stent. He underwent urgent surgical stent removal and patch angioplasty, achieving full recovery and maintaining patency at one year. Neither patient experienced perioperative neurological or cardiovascular complications. These cases highlight the feasibility and safety of surgical stent explantation in the management of carotid ISR. Compared with repeat endovascular interventions, surgical removal directly addresses the underlying mechanical and neointimal causes of restenosis and may provide superior long-term durability in appropriately selected patients. CEA with stent explantation represents an effective treatment option for ISR, particularly when endovascular options are limited by calcification, thrombus, or mechanical failure. Larger prospective studies are needed to establish patient selection criteria and optimize management strategies for this challenging clinical scenario.

PMID:41694952 | PMC:PMC12894099 | DOI:10.7759/cureus.101321

Gels. 2026 Jan 28;12(2):118. doi: 10.3390/gels12020118.

ABSTRACT

The physiological relevance of in vitro models is limited because conventional two-dimensional cell culture systems are unable to replicate the structural and functional complexity of native tissues. Extracellular matrix (ECM)-mimetic hydrogels have become important platforms for tissue engineering applications. This work developed hybrid hydrogels that mimic important biochemical and mechanical characteristics of cardiac tissue by combining decellularized bovine pericardium-derived (dBP) ECM, gellan gum (GG), and spermine (SPM). Although dBP offers tissue-specific biological cues, processing compromises its mechanical integrity. This limitation was overcome by adding GG, whose ionic gelation properties were optimized using DMEM and SPM. The hydrogels’ mechanical, biological, physicochemical, and structural characteristics were all evaluated. Under physiologically simulated conditions, the formulations showed quick gelation and long-term stability; scanning electron microscopy revealed an interconnected, ECM-like porous microarchitecture. While uniaxial compression testing provided Young’s modulus values comparable to native myocardium, rheological analysis revealed a concentration-dependent increase in storage modulus with increasing SPM content. H9C2 cardiomyoblasts were used in cytocompatibility studies to confirm that cell viability, morphology, and cytoskeletal organization were all preserved. All of these findings support the potential application of dBP-GG-SPM hydrogels in advanced in vitro cardiac models by showing that they successfully replicate important characteristics of cardiac ECM.

PMID:41744990 | PMC:PMC12939898 | DOI:10.3390/gels12020118

Ann Surg Oncol. 2026 Feb 12. doi: 10.1245/s10434-026-19228-6. Online ahead of print.

ABSTRACT

BACKGROUND: In this video demonstration, we highlight the robotic-assisted resection of a left retroperitoneal leiomyosarcoma and reconstruction of the left renal vein with a bovine pericardial patch.

PATIENT AND METHODS: The patient was placed supine on a split leg table, in 20 degrees of Trendelenburg. After the DaVinci Xi robot was docked, the posterior peritoneum was incised, lifting the right colon and cecum off the retroperitoneum. The peritoneum was temporarily tethered to the anterior abdominal wall using holding stitches. The right gonadal vein was identified and dissected into its insertion into the inferior vena cava (IVC). The IVC was skeletonized to identify the left renal vein. The left renal vein sarcoma was identified and circumferentially dissected. The left renal artery was clamped and proximal and distal control was obtained on the left renal vein. The anterior aspect of the left renal vein was excised en bloc with the sarcoma, with a margin of normal healthy appearing renal vein tissue. Using a 3 × 2 cm bovine pericardial patch, left renal vein reconstruction was performed using running 5-0 Goretex suture. Warm ischemia time was 35 min. The specimen was extracted through a lower midline incision.

RESULTS: The patient was discharged on postoperative day 2 after uneventful hospital course. Her renal function remained unchanged after surgery. Pathology confirmed grade 1 leiomyosarcoma with negative surgical margins.

CONCLUSIONS: With the use of the surgical robot, we demonstrate complete resection of a leiomyosarcoma with reconstruction of the left renal vein to allow preservation of renal function.

PMID:41678049 | DOI:10.1245/s10434-026-19228-6

ACS Biomater Sci Eng. 2026 Mar 9;12(3):1550-1564. doi: 10.1021/acsbiomaterials.5c01912. Epub 2026 Feb 19.

ABSTRACT

Subclinical leaflet thrombosis is a major cause of failure in both surgical and transcatheter bioprosthetic heart valves. Thromboresistance is a basic prerequisite for a cardiovascular biomaterial. In this study, bovine pericardium (BP) was decellularized and processed (DCL-BP) with 0.2% glutaraldehyde (GA) and covalently conjugated with amino acid derivatives. Hexylamides of L-Glutamic acid (Glutamyl dihexylamide-GHA), L-Lysine (Lysinyl hexylamide─LHA), and the propargyl derivative of L-Lysine (Lysinyl propargyl amide─K1 alk) were investigated. These modifications of BP generate three different scaffolds (DCL-GHA BP, DCL-LHA BP, and DCL-K1 alk BP) of varying surface energies and hydrophilic/phobic properties. The surface modifications altered the water contact angles of glutaraldehyde-processed pericardium from 59.25° to 67.74° in DCL-GHA BP and 79.98° in DCL-LHA BP, while DCL-K1 alk BP became highly hydrophilic such that the measurement of static angle was not feasible. Successful conjugations were confirmed by quenching of acid fuchsin color reaction and confocal Raman chemical mapping. The materials were found to be non-hemolytic and greatly reduced the overall protein adsorption and platelet adhesion, thus markedly improving the surface thromboresistance in vitro as observed by the whole blood clotting assay. The results of the ex vivo study in the sheep model correlated well with the in vitro data, where a marked reduction in protein adsorption from whole blood and platelet adhesion/thrombus deposition was observed, in comparison with the thrombogenic control. There was no activation of coagulation or complement system by any of the three test materials, making them non-thromboinflammatory and suitable candidate materials for use as a bioprosthetic heart valve leaflet.

PMID:41712900 | DOI:10.1021/acsbiomaterials.5c01912

North Clin Istanb. 2026 Feb 12;13(1):1-7. doi: 10.14744/nci.2026.39111. eCollection 2026.

ABSTRACT

OBJECTIVE: To assess the feasibility and early outcomes of single-stage hybrid revascularization consisting of common femoral endarterectomy with pericardial patch angioplasty and endovascular recanalization of the ipsilateral iliac arteries in patients with combined femoroiliac occlusive disease.

METHODS: Between January 2022 and October 2025, consecutive patients with multilevel iliofemoral peripheral artery disease (PAD) who underwent simultaneous single-stage hybrid revascularization at our institution were retrospectively analyzed. The hybrid strategy comprised common femoral endarterectomy with bovine pericardial patch angioplasty and intraoperative angiography-guided endovascular recanalization of the ipsilateral iliac arteries using balloon angioplasty with or without stent implantation; wire-guided iliac embolectomy was performed when indicated. Preoperative assessment included computed tomography angiography (1-mm slice thickness) and color-coded duplex ultrasonography. Patients were followed for at least three months with clinical assessment and duplex ultrasound. The primary endpoint was primary technical success of the planned hybrid procedure. Secondary endpoints included postoperative complications, length of hospital stay, three-month iliac stent patency, mortality, and amputation-free survival.

RESULTS: Twenty-eight patients were available for analysis. The median age was 73 (IQR: 14.5) years, and 64.3% were male. Most patients presented with advanced disease (Fontaine III-IV, 85.8%), and 60.7% had rest pain. Primary technical success was achieved in 85.7%. Bailout femorofemoral crossover bypass was required in 10.7%, and staged endovascular completion was planned in one patient. Iliac stenting was performed in 67.9%; wire-guided iliac embolectomy achieved thrombus extraction in 78.6% of attempted cases. The median length of stay was 10.5 (IQR:7) 13.4 days. Wound-healing disorders occurred in 7.1%. At three months, iliac stent patency was 100% and mortality was 0%. Amputation-free survival was 82.1%, with minor and major amputations in 10.7% and 7.1%, respectively.

CONCLUSION: Single-stage hybrid revascularization for femoroiliac occlusive disease in patients with advanced PAD was feasible and was associated with favorable early outcomes. Larger prospective studies with longer follow-up are needed to confirm durability and comparative effectiveness.

PMID:41940055 | PMC:PMC13047259 | DOI:10.14744/nci.2026.39111

BMJ Case Rep. 2026 Mar 25;19(3):e272043. doi: 10.1136/bcr-2026-272043.

ABSTRACT

We report the case of a man in his mid 70s with a history of coronary artery bypass grafting and prior surgical repair of an ascending aortic pseudoaneurysm using a bovine pericardial patch. He was subsequently found to have a persistent pseudoaneurysm adjacent to the right coronary ostium. In view of his prior sternotomy and the close proximity of the lesion to the coronary ostium, a transcatheter approach was selected. The pseudoaneurysm was successfully excluded using a duct occluder device, followed by deployment of a covered Papyrus coronary stent to reinforce the neck seal while preserving coronary flow. This case underscores the importance of multimodality imaging for diagnosis and procedural planning in complex, high-risk patients and demonstrates the feasibility of a dual-device transcatheter strategy for managing persistent aortic pseudoaneurysms in anatomically challenging locations.

PMID:41881477 | DOI:10.1136/bcr-2026-272043

Eur J Cardiothorac Surg. 2026 Mar 10;68(3):ezag097. doi: 10.1093/ejcts/ezag097.

ABSTRACT

OBJECTIVES: The availability and affordability of conduits have significantly challenged congenital heart surgery in low-resource settings. We present the intermediate-term outcomes of low-cost customized handmade conduits at our institution.

METHODS: Analysis of our surgical database and hospital information system (2016-2023) was done. Handmade conduits (cost: 30% of commercial conduits) were prepared in the operating room prior to surgery, using bovine pericardium for the conduit body tailored to the exact required diameter, with 0.1 mm polytetrafluoroethylene (PTFE) valve leaflets.

RESULTS: Handmade conduits were implanted in 185 patients [median age: 1.58 years (0.75-6.92), weight: 8.40 kg (6.30-17.03); conduit diameter 15 mm (13-20); cardiopulmonary bypass time 191.5 minutes (160-238) and cross-clamp time 106.5 minutes (73.8-145)]. Median ventilation duration was 19 hours (7-39), intensive care unit (ICU) stay 72 hours (44-120), and hospital stay 15 days (IQR: 11-20); mortality was 3.8%. The median follow-up duration was 29.5 months (14-59.5) for 160 patients. Peak conduit gradient on follow-up was 40 mm Hg (IQR: 22.8-63.8). Significant conduit regurgitation was noted in 21.2%. Endocarditis occurred in 7 (4.3%) patients (late in 4, early in 3). Re-interventions included 22 transcatheter procedures [18 balloon, 4 stents] at a median of 24 (12.2-34.7) months from conduit implantation. Of the 160 patients on follow-up, 28 had their conduits replaced at a median of 37 months (21-65 months) from implantation. Freedom from the composite end-point of reintervention/reoperation/death was 94% at 1 year; 70% at 5 years.

CONCLUSIONS: Handmade pericardial valved conduits are a potentially attractive low-cost alternative to commercially available conduits in low-resource settings.

PMID:41701157 | DOI:10.1093/ejcts/ezag097

Eur J Cardiothorac Surg. 2026 Mar 10;68(3):ezag097. doi: 10.1093/ejcts/ezag097.

ABSTRACT

OBJECTIVES: The availability and affordability of conduits have significantly challenged congenital heart surgery in low-resource settings. We present the intermediate-term outcomes of low-cost customized handmade conduits at our institution.

METHODS: Analysis of our surgical database and hospital information system (2016-2023) was done. Handmade conduits (cost: 30% of commercial conduits) were prepared in the operating room prior to surgery, using bovine pericardium for the conduit body tailored to the exact required diameter, with 0.1 mm polytetrafluoroethylene (PTFE) valve leaflets.

RESULTS: Handmade conduits were implanted in 185 patients [median age: 1.58 years (0.75-6.92), weight: 8.40 kg (6.30-17.03); conduit diameter 15 mm (13-20); cardiopulmonary bypass time 191.5 minutes (160-238) and cross-clamp time 106.5 minutes (73.8-145)]. Median ventilation duration was 19 hours (7-39), intensive care unit (ICU) stay 72 hours (44-120), and hospital stay 15 days (IQR: 11-20); mortality was 3.8%. The median follow-up duration was 29.5 months (14-59.5) for 160 patients. Peak conduit gradient on follow-up was 40 mm Hg (IQR: 22.8-63.8). Significant conduit regurgitation was noted in 21.2%. Endocarditis occurred in 7 (4.3%) patients (late in 4, early in 3). Re-interventions included 22 transcatheter procedures [18 balloon, 4 stents] at a median of 24 (12.2-34.7) months from conduit implantation. Of the 160 patients on follow-up, 28 had their conduits replaced at a median of 37 months (21-65 months) from implantation. Freedom from the composite end-point of reintervention/reoperation/death was 94% at 1 year; 70% at 5 years.

CONCLUSIONS: Handmade pericardial valved conduits are a potentially attractive low-cost alternative to commercially available conduits in low-resource settings.

PMID:41701157 | DOI:10.1093/ejcts/ezag097